Tanda, CEO of Aptar: Inflation less of a concern in the pharmaceutical sector
February 12, 2024 at 03:32 pm EST
Share
(MT Newswires) -- Stephan Tanda, CEO of Aptar, discusses the current state of the economy and the impact of inflation on consumers. He points out that, although inflation is more moderate, consumer salaries have increased compared to the pre-pandemic period, which maintains their purchasing power. In his opinion, innovation continues to stimulate consumer interest, even in a context of high prices.
In the pharmaceutical sector, Tanda notes that inflation is less of a concern for consumers, who prioritise access to medicines. He notes a certain reluctance on the part of consumers to spend on personal care and home maintenance products, which are considered to be commodities.
Inflation in the United States is expected to have risen by 3.7% in January compared with a year earlier. This would be the smallest year-on-year increase since April 2021.
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.
APTARGROUP, INC. 
